Bio-Rad Laboratories, Inc. Class A Common Stock vs OneSpan Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.43B), while OneSpan Inc trades at $16.25 (market cap $600.69M). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 15.7× OneSpan Inc's market cap, and OneSpan Inc pays a 3.19% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | OSPN | |
|---|---|---|
Market Cap | $9.43B | $600.69M |
Sector | Health | Technology |
52-Week High | $356.25 | $16.78 |
52-Week Low | $241.71 | $10.15 |
Enterprise Value | $9.18B | $569.77M |
Dividend Yield | — | 3.19% |
Trailing returns across standard periods
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →